Literature DB >> 15785046

The psoriasis area and severity index is the adequate criterion to define severity in chronic plaque-type psoriasis.

Jochen Schmitt1, Gottfried Wozel.   

Abstract

BACKGROUND: Chronic plaque-type psoriasis is a major dermatosis, but a significant question is still unanswered: What defines severity in chronic plaque-type psoriasis? While objective assessments like the Psoriasis Area and Severity Index (PASI) have frequently been used in clinical trials, quality of life (QOL) questionnaires are currently becoming more and more popular.
OBJECTIVE: This article summarizes the most important objective and subjective measurements of severity in psoriasis. For every dermatologist it is critically important to distinguish between severe psoriasis and psoriasis that severely affects QOL. Even if the PASI also has disadvantages, it is the most adequate instrument available to evaluate severity in plaque-type psoriasis. RESULT: We provide reasons why PASI >12 defines severe, PASI 7-12 moderate and PASI <7 mild chronic plaque-type psoriasis.

Entities:  

Mesh:

Year:  2005        PMID: 15785046     DOI: 10.1159/000083509

Source DB:  PubMed          Journal:  Dermatology        ISSN: 1018-8665            Impact factor:   5.366


  84 in total

Review 1.  [A decade of biologics in dermatology].

Authors:  G Wozel; M Meurer
Journal:  Hautarzt       Date:  2012-04       Impact factor: 0.751

2.  Which clinical variables have the most significant correlation with quality of life evaluated by SF-36 survey in Croatian cohort of patient with ankylosing spondylitis and psoriatic arthritis?

Authors:  Zrinka Jajić; Ivana Rajnpreht; Nataša Kovačić; Ivan Krešimir Lukić; Vedran Velagić; Frane Grubišić; Ana Marušić; Danka Grčević
Journal:  Rheumatol Int       Date:  2011-11-08       Impact factor: 2.631

3.  [Psychosocial factors in psoriasis. A pilot study].

Authors:  J A Bahmer; F Petermann; J Kuhl
Journal:  Hautarzt       Date:  2007-11       Impact factor: 0.751

4.  Carotid intima-media thickness and epicardial fat thickness predict precoronary artery disease status in psoriasis.

Authors:  Banavasi Shanmukha Girisha; Shajahan Shibina; U Raghuraja; K Subramanyam
Journal:  Indian J Dermatol Venereol Leprol       Date:  2021 May-Jun       Impact factor: 2.545

5.  Peptidoglycan recognition proteins Pglyrp3 and Pglyrp4 are encoded from the epidermal differentiation complex and are candidate genes for the Psors4 locus on chromosome 1q21.

Authors:  Chao Sun; Punam Mathur; Josée Dupuis; Rich Tizard; Barry Ticho; Tom Crowell; Humphrey Gardner; Anne M Bowcock; John Carulli
Journal:  Hum Genet       Date:  2005-12-17       Impact factor: 4.132

6.  Methylenetetrahydrofolate reductase (MTHFR) 677C>T gene polymorphism as a possible factor for reducing clinical severity of psoriasis.

Authors:  Ercan Karabacak; Ersin Aydin; Omer Ozcan; Bilal Dogan; Mustafa Gultepe; Alpaslan Cosar; Tuba Muftuoglu
Journal:  Int J Clin Exp Med       Date:  2014-03-15

7.  Evaluation of Ixekizumab Treatment for Patients With Pityriasis Rubra Pilaris: A Single-Arm Trial.

Authors:  Dylan Haynes; Jennifer L Strunck; Christina A Topham; Alex G Ortega-Loayza; Gail Kent; Pamela B Cassidy; Ronghua Hu; Keith Choate; Zhiping Wang; Yuangang Liu; Teri M Greiling
Journal:  JAMA Dermatol       Date:  2020-06-01       Impact factor: 10.282

Review 8.  [Therapeutic strategies for psoriasis and psoriatic arthritis].

Authors:  G Wozel
Journal:  Hautarzt       Date:  2009-02       Impact factor: 0.751

9.  Beta-defensin-2 protein is a serum biomarker for disease activity in psoriasis and reaches biologically relevant concentrations in lesional skin.

Authors:  Patrick A M Jansen; Diana Rodijk-Olthuis; Edward J Hollox; Marijke Kamsteeg; Geuranne S Tjabringa; Gys J de Jongh; Ivonne M J J van Vlijmen-Willems; Judith G M Bergboer; Michelle M van Rossum; Elke M G J de Jong; Martin den Heijer; Andrea W M Evers; Mieke Bergers; John A L Armour; Patrick L J M Zeeuwen; Joost Schalkwijk
Journal:  PLoS One       Date:  2009-03-06       Impact factor: 3.240

10.  The health-related quality of life in rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis: a comparison with a selected sample of healthy people.

Authors:  Fausto Salaffi; Marina Carotti; Stefania Gasparini; Michele Intorcia; Walter Grassi
Journal:  Health Qual Life Outcomes       Date:  2009-03-18       Impact factor: 3.186

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.